These drugs are supposed to be of benefit in treating and reducing cardiovascular events.

If a drug drops LDL significantly but does not reduce cardiovascular events significantly then what is the point of using it? To treat a number?

While it will not necessarily be a direct competitor to Apabetalone, it could certainly steal our thunder if another “cholesterol pill” comes on the market and can reduce MACE.

The LDL hypothesis is strong at this point so if a clinician had a choice between ESPR’s drug or Apabetalone as an add on therapy (imagining they both have similar effects on MACE), they would choice the former.

bfw